Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Meda in-licenses Ceplene from EpiCept; later buys full rights; Immune Pharmaceuticals repurchases rights

Executive Summary

Meda AB (specialty pharmaceuticals) will exclusively sell cancer and pain drug developer EpiCept's acute myeloid leukemia therapy Ceplene (histamine dihydrochloride) in Europe, Japan, China, Australia, and other undisclosed Asian countries.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register